Search
Basic Fibroblast Growth Factor
go.drugbank.com/drugs/DB14131InvestigationalBasic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. … The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages.
CRx-401
go.drugbank.com/drugs/DB05775ExperimentalIt consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. … CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain.
Fucoxanthin
go.drugbank.com/drugs/DB15462InvestigationalFucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. … A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing.
SARS-CoV-2 Sclamp
go.drugbank.com/drugs/DB15849InvestigationalThe vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalIt has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. … CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses.
INO-4800
go.drugbank.com/drugs/DB15693Investigational[A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19.
Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. … Eculizumab is a monoclonal antibody that targets complement protein C5.
Kava
go.drugbank.com/drugs/DB01322ApprovedInvestigationalNutraceuticalWithdrawnCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 CYP1A2 Inhibitors17alpha-methyl-4-hydroxynandrolone
go.drugbank.com/drugs/DB01540ExperimentalIllicit17alpha-methyl-4-hydroxynandrolone is a schedule 3 anabolic steroid.
Methyl-1-testosterone
go.drugbank.com/drugs/DB01572ExperimentalIllicitIt is a derivative of 1-testosterone with a methyl group in the carbon 17. Methyl-1-testosterone is considered a prohibited doping substance. … Methyl-1-testosterone is a synthetic and orally active anabolic–androgenic steroid (AAS) which was never marketed for medical use.